Here's how BIORXIV.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

BIORXIV . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Biorxiv.org Make Money
  6. Keywords
  7. Topics
  8. Social Networks
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We are analyzing https://www.biorxiv.org/content/10.1101/2024.06.06.597720v2.

Title:
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection | bioRxiv
Description:
Monoclonal antibody (mAb) therapeutics hold promise for both preventing and treating infectious diseases, especially among vulnerable populations. However, the emergence of various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents challenges for current mAb treatments, emphasizing the need for more potent and broadly neutralizing antibodies. In this study, we employed an unbiased screening approach to discover broadly neutralizing antibodies and successfully isolated two mAbs from individuals with only exposure to ancestral SARS-CoV-2. One of these antibodies, CYFN1006-1, exhibited robust cross-neutralization against a spectrum of SARS-CoV-2 variants, including the latest JN.1 and KP.2 variants, with consistent IC50 values ranging from ∼1 to 5 ng/mL. Notably, it also displayed broad neutralization activity against SARS-CoV and related sarbecoviruses, such as WIV1, SHC014, RaTG13, and GD-Pangolin. Structural analysis revealed that these mAbs target shared hotspot but mutation-resistant epitopes, with their Fabs locking the RBD in the “down” conformation through interactions with adjacent Fabs and RBDs, and cross-linking Spike trimers into di-trimers to block viral infection. In vivo studies conducted in a JN.1-infected hamster model validated the protective efficacy of CYFN1006-1, emphasizing its therapeutic potential. These findings suggest that, through meticulous approaches, rare antibodies with cross-neutralization activities against SARS-CoV-2 and related sarbecoviruses can be identified from individuals with exclusively ancestral virus exposure. ### Competing Interest Statement Y.G. is co-founder and shareholder of Antibody BioPharm, Inc. and ChangYuan FuNeng (Shanghai) Life Technology Co., Ltd. The authors declare that they have no other competing interests.
Website Age:
12 years and 2 months (reg. 2013-04-08).

Matching Content Categories {📚}

  • Science
  • Education
  • Family & Parenting

Content Management System {📝}

What CMS is biorxiv.org built with?

Website use Drupal 7 (http://drupal.org).

Traffic Estimate {📈}

What is the average monthly size of biorxiv.org audience?

💥 Very Strong Traffic: 200k - 500k visitors per month


Based on our best estimate, this website will receive around 250,037 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Biorxiv.org Make Money? {💸}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Biorxiv.org might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

biology, sarscov, antibodies, medrxiv, subject, reviews, clinical, preprint, broadly, neutralizing, sarbecoviruses, ancestral, wang, variants, technology, biorxiv, university, microbiology, trials, epidemiology, search, results, potent, infection, lei, chen, pdf, antibody, mab, emphasizing, mabs, individuals, exposure, cyfn, crossneutralization, related, fabs, competing, authors, copyright, license, institute, cancer, context, genetics, papers, submitted, cookies, skip, main,

Topics {✒️}

epidemiology subject categories clinical trials exhibited robust cross-neutralization microbiology cross-linking spike trimers biorxiv subject category genetics epidemiology papers reviews ancestral sars-cov-2 block viral infection author/funder cross-neutralization activities keyword advanced search health-related information broadly neutralizing antibodies therapeutics hold promise treating infectious diseases unbiased screening approach structural analysis revealed mutation-resistant epitopes vivo studies conducted generous financial support chan zuckerberg initiative imperial college london vrije universiteit amsterdam articles animal behavior competing interest statement current mab treatments sars-cov-2 variants context antibody biopharm lei sun sars-cov-2 sars-cov yajie wang xun wang di-trimers rare antibodies competing interests related sarbecoviruses results follow sarbecoviruses elicited yuanchen liu xiaomin xing chen li jialu shi wentai ma jiayan li yanjia chen

Social Networks {👍}(4)

External Links {🔗}(5)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • jQuery
  • Modernizr

Emails and Hosting {✉️}

Mail Servers:

  • usb-smtp-inbound-1.mimecast.com
  • usb-smtp-inbound-2.mimecast.com

Name Servers:

  • jen.ns.cloudflare.com
  • vin.ns.cloudflare.com

CDN Services {📦}

  • Jsdelivr

7.1s.